Cargando…
Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
Extraskeletal myxoid chondrosarcoma (EMCS) is an undifferentiated mesenchymal malignancy; however, its immune microenvironment remains to be elucidated. The case of a 34‐year‐old woman who developed EMCS metastasizing to the pleura is presented here. The pleural EMCS showed hypervascularity, absent...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527174/ https://www.ncbi.nlm.nih.gov/pubmed/35974707 http://dx.doi.org/10.1111/1759-7714.14613 |
_version_ | 1784801026767847424 |
---|---|
author | Ogata, Ryosuke Soda, Hiroshi Senju, Hiroaki Fujioka, Masaki Shimada, Midori Yamashita, Koki Irifune, Satoshi Tagawa, Ryuta Dotsu, Yosuke Iwasaki, Keisuke Taniguchi, Hirokazu Takemoto, Shinnosuke Fukuda, Yuichi Mukae, Hiroshi |
author_facet | Ogata, Ryosuke Soda, Hiroshi Senju, Hiroaki Fujioka, Masaki Shimada, Midori Yamashita, Koki Irifune, Satoshi Tagawa, Ryuta Dotsu, Yosuke Iwasaki, Keisuke Taniguchi, Hirokazu Takemoto, Shinnosuke Fukuda, Yuichi Mukae, Hiroshi |
author_sort | Ogata, Ryosuke |
collection | PubMed |
description | Extraskeletal myxoid chondrosarcoma (EMCS) is an undifferentiated mesenchymal malignancy; however, its immune microenvironment remains to be elucidated. The case of a 34‐year‐old woman who developed EMCS metastasizing to the pleura is presented here. The pleural EMCS showed hypervascularity, absent PD‐L1 expression, and a lack of tumor mutational burden and pathogenic variants. Immunohistological examination of the pleural lesions showed predominant M2 macrophages and sparse CD8(+) T cells. EMCS and the tumor stroma were positive for transforming growth factor‐β1 (TGF‐β1) and vascular endothelial growth factor (VEGF). In contrast, a small number of the stromal vessels were positive for hypoxia inducible factor‐1α (HIF‐1α). TGF‐β1 and VEGF in the tumor stroma and low antigenicity of the tumor cells may help explain how EMCS induced the immunosuppressive microenvironment. These findings may encourage investigators to explore novel combined immunotherapy for EMCS, such as TGF‐β1 and VEGF inhibitors, and specific therapy for enhancing tumor antigens. |
format | Online Article Text |
id | pubmed-9527174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-95271742022-10-06 Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases Ogata, Ryosuke Soda, Hiroshi Senju, Hiroaki Fujioka, Masaki Shimada, Midori Yamashita, Koki Irifune, Satoshi Tagawa, Ryuta Dotsu, Yosuke Iwasaki, Keisuke Taniguchi, Hirokazu Takemoto, Shinnosuke Fukuda, Yuichi Mukae, Hiroshi Thorac Cancer Case Reports Extraskeletal myxoid chondrosarcoma (EMCS) is an undifferentiated mesenchymal malignancy; however, its immune microenvironment remains to be elucidated. The case of a 34‐year‐old woman who developed EMCS metastasizing to the pleura is presented here. The pleural EMCS showed hypervascularity, absent PD‐L1 expression, and a lack of tumor mutational burden and pathogenic variants. Immunohistological examination of the pleural lesions showed predominant M2 macrophages and sparse CD8(+) T cells. EMCS and the tumor stroma were positive for transforming growth factor‐β1 (TGF‐β1) and vascular endothelial growth factor (VEGF). In contrast, a small number of the stromal vessels were positive for hypoxia inducible factor‐1α (HIF‐1α). TGF‐β1 and VEGF in the tumor stroma and low antigenicity of the tumor cells may help explain how EMCS induced the immunosuppressive microenvironment. These findings may encourage investigators to explore novel combined immunotherapy for EMCS, such as TGF‐β1 and VEGF inhibitors, and specific therapy for enhancing tumor antigens. John Wiley & Sons Australia, Ltd 2022-08-16 2022-10 /pmc/articles/PMC9527174/ /pubmed/35974707 http://dx.doi.org/10.1111/1759-7714.14613 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Ogata, Ryosuke Soda, Hiroshi Senju, Hiroaki Fujioka, Masaki Shimada, Midori Yamashita, Koki Irifune, Satoshi Tagawa, Ryuta Dotsu, Yosuke Iwasaki, Keisuke Taniguchi, Hirokazu Takemoto, Shinnosuke Fukuda, Yuichi Mukae, Hiroshi Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases |
title | Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases |
title_full | Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases |
title_fullStr | Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases |
title_full_unstemmed | Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases |
title_short | Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases |
title_sort | immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: a case of pleural metastases |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527174/ https://www.ncbi.nlm.nih.gov/pubmed/35974707 http://dx.doi.org/10.1111/1759-7714.14613 |
work_keys_str_mv | AT ogataryosuke immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT sodahiroshi immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT senjuhiroaki immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT fujiokamasaki immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT shimadamidori immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT yamashitakoki immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT irifunesatoshi immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT tagawaryuta immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT dotsuyosuke immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT iwasakikeisuke immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT taniguchihirokazu immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT takemotoshinnosuke immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT fukudayuichi immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases AT mukaehiroshi immunosuppressivetumormicroenvironmentinextraskeletalmyxoidchondrosarcomaacaseofpleuralmetastases |